Senna Syrup
NDC Package 81033-120-55
Package Information
Senna Syrup syrups is sennosides are used to treat constipation. This formulation utilizes a syrup delivery system. Marketed by Kesin Pharma Corporation, this product is identified by NDC 81033-120 and is authorized under FDA application M007.
Identification & Billing
- RxCUI: 702311 - sennosides 8.8 MG in 5 mL Oral Solution
- RxCUI: 702311 - sennosides, USP 1.76 MG/ML Oral Solution
- RxCUI: 702311 - sennosides 8.8 MG per 5 mL Oral Syrup
- RxCUI: 702311 - sennosides, USP 26.4 MG per 15 ML Oral Solution
- RxCUI: 702311 - sennosides, USP 8.8 MG per 5 ML Oral Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 81033 - Kesin Pharma Corporation
- 81033-120 - Senna Syrup
- 81033-120-55 - 50 CUP, UNIT-DOSE in 1 CARTON / 15 mL in 1 CUP, UNIT-DOSE (81033-120-15)
- 81033-120 - Senna Syrup
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (81033-120). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 81033-120-55 identifies a specific commercial package of 50 cup, unit-dose in 1 carton / 15 ml in 1 cup, unit-dose (81033-120-15) of Senna Syrup, a human over the counter drug labeled by Kesin Pharma Corporation. This syrup is formulated for oral use and contains sennosides as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Kesin Pharma Corporation on May 26, 2025. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Sennosides are used to treat constipation. They may also be used to clean out the intestines before a bowel examination/surgery. Sennosides are known as stimulant laxatives. They work by keeping water in the intestines, which causes movement of the intestines.
How is this Kesin Pharma Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 81033012055. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.